- Home
- CTRM vs ACHL Comparison
CTRM vs ACHL Comparison
Compare CTRM & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- ACHL
- Stock Information
- Founded
- CTRM 2016
- ACHL 2016
- Country
- CTRM Cyprus
- ACHL United Kingdom
- Employees
- CTRM N/A
- ACHL N/A
- Industry
- CTRM Marine Transportation
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTRM Consumer Discretionary
- ACHL Health Care
- Exchange
- CTRM Nasdaq
- ACHL Nasdaq
- Market Cap
- CTRM 37.6M
- ACHL 40.4M
- IPO Year
- CTRM N/A
- ACHL 2021
- Fundamental
- Price
- CTRM $3.57
- ACHL $1.06
- Analyst Decision
- CTRM
- ACHL Hold
- Analyst Count
- CTRM 0
- ACHL 3
- Target Price
- CTRM N/A
- ACHL $2.83
- AVG Volume (30 Days)
- CTRM 63.4K
- ACHL 146.9K
- Earning Date
- CTRM 11-07-2024
- ACHL 11-14-2024
- Dividend Yield
- CTRM N/A
- ACHL N/A
- EPS Growth
- CTRM N/A
- ACHL N/A
- EPS
- CTRM 2.39
- ACHL N/A
- Revenue
- CTRM $76,443,340.00
- ACHL N/A
- Revenue This Year
- CTRM N/A
- ACHL N/A
- Revenue Next Year
- CTRM N/A
- ACHL N/A
- P/E Ratio
- CTRM $1.49
- ACHL N/A
- Revenue Growth
- CTRM N/A
- ACHL N/A
- 52 Week Low
- CTRM $3.01
- ACHL $0.63
- 52 Week High
- CTRM $6.50
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- CTRM 36.45
- ACHL 60.69
- Support Level
- CTRM $3.78
- ACHL $1.01
- Resistance Level
- CTRM $4.18
- ACHL $1.08
- Average True Range (ATR)
- CTRM 0.15
- ACHL 0.04
- MACD
- CTRM -0.02
- ACHL -0.00
- Stochastic Oscillator
- CTRM 18.67
- ACHL 53.85
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under two reportable segments namely Dry bulk; Aframax/LR2 tanker; Handysize tanker and Container ship. It generates maximum revenue from the Dry bulk segment.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.